These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3555956)

  • 21. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G; Kopp HP; Ristic S; Muzyka B; Peter L; Mitteregger G
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane.
    Ward GM; Simpson RW; Ward EA; Turner RC
    Diabetologia; 1981 Oct; 21(4):383-6. PubMed ID: 7026334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of premixed with patient-mixed insulins.
    Corcoran JS; Yudkin JS
    Diabet Med; 1986 May; 3(3):246-9. PubMed ID: 2951178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens.
    Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW
    Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.
    Nielsen FS; Jørgensen LN; Ipsen M; Voldsgaard AI; Parving HH
    Diabetologia; 1995 May; 38(5):592-8. PubMed ID: 7489843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-four-hour metabolic profiles in diabetic children receiving insulin injections once or twice daily.
    Werther GA; Jenkins PA; Turner RC; Baum JD
    Br Med J; 1980 Aug; 281(6237):414-8. PubMed ID: 7000260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin.
    Parillo M; Mura A; Iovine C; Rivellese AA; Lavicoli M; Riccardi G
    Diabetes Care; 1992 Feb; 15(2):173-7. PubMed ID: 1547673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with NovoPen II and insulin Protaphane HM Penfill.
    Kølendorf K; Beck-Nielsen H; Oxenbøll B
    Postgrad Med J; 1988; 64 Suppl 3():14-6; discussion 21. PubMed ID: 3074294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of blood glucose profile and glycemic control in type 1 diabetic patients treated with Actrapid-Monotard or Actrapid Protaphane (NPH) human insulins.
    Buysschaert M; Minette P; Ketelslegers JM; Pairet JV; Vogels M; Lambert AE
    Diabetes Res; 1987 Jan; 4(1):31-3. PubMed ID: 3552364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of single- and split-dose insulin regimens with 24-hour monitoring.
    Langdon DR; James FD; Sperling MA
    J Pediatr; 1981 Dec; 99(6):854-61. PubMed ID: 7031208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life.
    Taylor R; Foster B; Kyne-Grzebalski D; Vanderpump M
    Diabet Med; 1994 Jul; 11(6):551-7. PubMed ID: 7955971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of twice daily regimens of Actrapid and Monotard insulins.
    Akintewe TA
    East Afr Med J; 1985 Mar; 62(3):196-9. PubMed ID: 3893969
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of Monotard and Ultratard insulin at bedtime in a model of optimized insulin therapy in Italy.
    Martina V; Tagliabue M; Maccario M; D'Antona G; Camanni F
    Diabete Metab; 1989; 15(6):372-4. PubMed ID: 2697606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations.
    Castillo M; Nemery A; Verdin E; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1983; 25(6):767-71. PubMed ID: 6363099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of the time interval between insulin injection and breakfast in determining postprandial glycaemic control--a comparison between human and porcine insulin.
    Patrick AW; Collier A; Matthews DM; Macintyre CC; Clarke BF
    Diabet Med; 1988 Jan; 5(1):32-5. PubMed ID: 2964325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical comparison of purified bovine and purified porcine insulins.
    Olczak SA; Greenwood RH
    Postgrad Med J; 1985 Jan; 61(711):15-8. PubMed ID: 3887349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of glycaemic control in diabetic patients treated with morning or evening human ultratard insulin.
    Edsberg B; Dejgaard A; Kühl C
    Diabet Med; 1987; 4(1):53-5. PubMed ID: 2951221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin.
    Dorchy H; Duchateau J; D'Hooge D
    Diabete Metab; 1988; 14(4):415-21. PubMed ID: 3066649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
    Jørgensen S; Vaag A; Langkjaer L; Hougaard P; Markussen J
    BMJ; 1989 Aug; 299(6696):415-9. PubMed ID: 2506998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bolus/basal multiple injection regimen in type I diabetes. A multicentre trial using a new 'fountain-pen' device for short-acting human insulin as well as long-acting human insulin.
    Distiller LA; Robertson LI; Moore R; Bonnici F
    S Afr Med J; 1987 Jun; 71(12):749-52. PubMed ID: 3299758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.